Nivolumab biosimilar - Prestige Biopharma
Alternative Names: PBP-2101Latest Information Update: 19 Feb 2022
At a glance
- Originator Prestige BioPharma
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Urogenital cancer
Most Recent Events
- 08 Feb 2022 Early research in Urogenital cancer (Metastatic disease) in Singapore (Parenteral) (Prestige Biopharma pipeline, February 2022)